1. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma

   • Frederick W. Thielen
   • Nasuh C. Büyükkaramikli
   • Isaac Corro Ramos

   Review Article Open access 13 December 2018 Pages: 975 - 984

2. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal

   • Becky Pennington
   • Shije Ren
   • Steven J. Edwards

   Review Article 22 November 2018 Pages: 985 - 993

   

3. Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review

   • Nikolaos Maniadakis
   • Evgenia Konstantakopoulou

   Systematic Review 22 April 2019 Pages: 995 - 1010

   

4. Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review

   • Stuart J. Wright
   • William G. Newman
   • Katherine Payne

   Systematic Review Open access 13 May 2019 Pages: 1011 - 1027

   

5. The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective

   • Simon Frey
   • Tom Stargardt
   • Jonas Schreyögg

   Original Research Article 04 April 2019 Pages: 1029 - 1039

6. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck

   • Kim Cocks
   • Marta Contente
   • James W. Shaw

   Original Research Article Open access 10 April 2019 Pages: 1041 - 1047

   

7. Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions

   • Mutsa Gumbie
   • Bonny Parkinson
   • Virginia Mumford

   Original Research Article 09 May 2019 Pages: 1049 - 1064

   

8. Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

   • Katrine Wallace
   • Sandra Goble
   • Josh Bedel

   Letter to the Editor Open access 07 June 2019 Pages: 1065 - 1067

9. Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)

   • Hui Shao
   • Vivian Fonseca
   • Lizheng Shi

   Correction 16 May 2019 Pages: 1069 - 1069

10. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

    • Mark Bounthavong
    • Javed Butler
    • David L. Veenstra

    Correction 14 May 2019 Pages: 1071 - 1071